Coherus BioSciences (NASDAQ:CHRS – Get Free Report) had its target price increased by research analysts at HC Wainwright from $11.00 to $12.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Other research analysts have also recently issued research […] Read this story
